The presently disclosed subject matter relates to use of Schwann cell precursors and Schwann cells derived from stem cells (e.g., human stem cells) for drug discovery in regeneration of peripheral nervous system (PNS) and/or central nervous system (CNS), prevention and/or repair myelin damages, and/or prevention and/or treatment of Schwann cell-related disorder (e.g., peripheral neuropathy diabetic peripheral neuropathy).